Compared to chemical antibiotics, AMPs are particularly attractive for several reasons: (i) AMPs appear to have a lower rate of inducing bacterial resistance and they continue to be developed clinically (Spohn et al., 2019); (ii) AMPs appear to be the last resort for recalcitrant infections as exemplified by Polymyxin B, colistin, daptomycin against the MDR ESKAPE pathogens (Zavascki et al., 2007); (iii) AMPs can work synergistically with antibiotics (Sheard et al., 2019). The gene discussed is ADSL; the disease is infection.